Methodologies used in cost-effectiveness models for evaluating treatments in major depressive disorder: a systematic review
Open Access
- 1 January 2012
- journal article
- review article
- Published by Springer Nature in Cost Effectiveness and Resource Allocation
- Vol. 10 (1) , 1
Abstract
Decision makers in many jurisdictions use cost-effectiveness estimates as an aid for selecting interventions with an appropriate balance between health benefits and costs. This systematic literature review aims to provide an overview of published cost-effectiveness models in major depressive disorder (MDD) with a focus on the methods employed. Key components of the identified models are discussed and any challenges in developing models are highlighted.Keywords
This publication has 71 references indexed in Scilit:
- Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland☆Journal of Affective Disorders, 2010
- Antidepressants versus placebo for depression in primary careCochrane Database of Systematic Reviews, 2009
- Healthy-years equivalent: wounded but not yet deadExpert Review of Pharmacoeconomics & Outcomes Research, 2009
- Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in GermanyThe European Journal of Health Economics, 2005
- Evidence of cost-effective treatments for depression: a systematic reviewJournal of Affective Disorders, 2005
- Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in AustriaCurrent Medical Research and Opinion, 2004
- A Comparison of the Direct Costs and Cost Effectiveness of Serotonin Reuptake Inhibitors and Associated Adverse Drug ReactionsCNS Drugs, 2004
- Pharmacoeconomic analysis of antidepressants for major depressive disorder in the United Kingdom.PharmacoEconomics, 2000
- Recovery from depression, work productivity, and health care costs among primary care patientsGeneral Hospital Psychiatry, 2000
- EuroQol: the current state of playHealth Policy, 1996